[{"id":"d7c1dd23-b592-49e2-9ffb-7f723f3c6b6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010901","created_at":"2023-08-25T15:08:21.904Z","updated_at":"2024-07-02T16:35:22.516Z","phase":"Phase 1","brief_title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","source_id_and_acronym":"NCT06010901","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 01/13/2024","start_date":" 01/13/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-23"},{"id":"6bdce55b-ef4a-469e-8114-7ca9780e7472","acronym":"","url":"https://clinicaltrials.gov/study/NCT05834543","created_at":"2023-04-28T15:04:40.318Z","updated_at":"2024-07-02T16:35:49.345Z","phase":"Phase 1/2","brief_title":"Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT05834543","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Anniko (penpulimab-kcqx) • TQB2618"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-28"},{"id":"394b8ab4-da79-4d31-92c2-e88c738add9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05400876","created_at":"2022-06-02T16:58:53.336Z","updated_at":"2024-07-02T16:35:55.602Z","phase":"Phase 1/2","brief_title":"To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma","source_id_and_acronym":"NCT05400876","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Anniko (penpulimab-kcqx) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-02-14"},{"id":"565d9c7a-c834-4faa-9d14-ac630ac812dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645315","created_at":"2022-12-09T14:57:48.849Z","updated_at":"2024-07-02T16:35:59.356Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05645315","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • ALK • ROS1 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation","tags":["EGFR • ALK • ROS1 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Andewei (benmelstobart) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 127","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-12-09"}]